JD Supra

FDA Moves to Shut the Door on Large-Scale Compounding of GLP-1 Drugs

On April 30, 2026, the U.S. Food and Drug Administration announced that it is proposing to exclude semaglutide, tirzepatide, and liraglutide from ...

FDA Moves To Block Some Compounded GLP-1s—Here’s What It Means For Online Prescriptions

Compounded semaglutide, tirzepatide and liraglutide could be harder to come by starting this summer, if the U.S. Food and ...
Stocktwits on MSN

FDA moves to block compounded versions of popular weight-loss drugs – NVO, LLY stocks gain

Semaglutide, the key ingredient in Novo Nordisk’s Wegovy and Ozempic, and Tirzepatide, sold by Eli Lilly as Zepbound and Mounjaro, would be excluded from bulk compounding. ・The 503B Bulk List features ...

US FDA proposes excluding weight-loss drugs from compounding list

April 30 (Reuters) - The U.S. Food and Drug Administration on Thursday proposed excluding active ingredients for Novo Nordisk ...

FDA proposes excluding Novo, Lilly weight loss drugs from bulk compounding list in win for the companies

If that proposal is finalized, the exclusion would likely limit the mass compounding of those medicines ​unless they appear ...